The company also announced unwinding of a transaction amounting to Rs 2,238 crore with Atlas Global Trading and initiated steps to induct S R B C & Co LLP, its statutory auditors, as auditors of subsidiaries.Shares of Sun Pharma were trading 5.In November 2018, a whistleblower approached Sebi with a document alleging various irregularities by the company, its promoter and others.”We are concerned that certain entities/individuals are adopting unfair trade practices prejudicial to the interest of shareholders and other stakeholders,” the company had said in the letter, a copy of which has been submitted to the stock exchanges.”The said funding was included garden parasols in loans and advances schedule of Sun Pharmas 2017-18 consolidated balance sheet,” it added.95 apiece on BSE.Sun Pharma said this change will be made effective by first quarter of 2019-20, post receipt of all requisite regulatory approvals.”This liability was in respect of Atlas assuming the damages on account of Protonix patent litigation settlement entered by Sun Pharma which was disclosed in Sun Pharmas annual report 2013-14,” the company said.
Sun Pharma would like to dispel all falsehoods being spread about its financial dealings with Suraksha Realty.”Sun Pharmas distribution related to India domestic formulations business shall be transitioned from Aditya Medisales Ltd.Regarding loans or guarantees to Suraksha Realty, Sun Pharma said, “neither any loans nor guarantees have been given to Suraksha Realty..17 per cent higher at Rs 418.Amid reports that a second whistleblower complaint has been filed against it and shares taking a beating on the exchanges, Sun Pharma had written to Sebi flagging concerns that certain entities were allegedly adopting unfair trade practices.New Delhi: Sun Pharma on Tuesday replaced its domestic formulations distributor Aditya Medisales with its own subsidiary in the backdrop of a second whistleblower complaint filed against the company.Last week, Sun Pharmaceutical asked markets regulator Sebi to look into the issues of certain entities and individuals allegedly adopting unfair trade practices prejudicial to the companys shareholders. This transaction is expected to be concluded in 2018-19,” the company added.Sun Pharma said it has also initiated steps to induct S R B C & Co LLP, its statutory auditors, as auditors of subsidiaries that are currently audited by Valia & Timbadia.In September 2014, Sun Pharmas Halol facility (Gujarat) was impacted by USFDA cGMP issues which were finally resolved in June 2018, after nearly four years
paddled